Mecanismo de acción, farmacología e interacciones de dolutegravirMechanisms of action, pharmacology and interactions of dolutegravir
References (0)
Cited by (12)
5-Hydroxypyrido[2,3-b]pyrazin-6(5H)-one derivatives as novel dual inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H and integrase
2018, European Journal of Medicinal ChemistryCitation Excerpt :Up to now, there are four strand transfer IN inhibitors (INSTIs) approved by the U. S. Food and Drug Administration (FDA) (Fig. 2). These drugs are raltegravir (RAL) [25], elvitegravir (EVG) [26], dolutegravir (DTG) [27], and bictegravir [28]. All of them share similar structural features with RNase H inhibitors, including the coplanar triad of heteroatoms and a terminal hydrophobic aryl moiety.
Effect of dihydroartemisinin/piperaquine for malaria intermittent preventive treatment on dolutegravir exposure in pregnant women living with HIV
2022, Journal of Antimicrobial ChemotherapyDevelopment and Validation of Stability Indicating Related Substances Method for Dolutegravir/Lamivudine/Tenofovir Disoproxil Fumarate (DLT) Tablets using High Performance Liquid Chromatography
2022, Research Journal of Pharmacy and TechnologySwitching to a NRTI-free 2 drug regimen (2DR) –a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes
2021, HIV Research and Clinical Practice
Copyright © 2015 Elsevier España, S.L.U. All rights reserved.